CompletedNot Applicable

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

United States, Russia61 participantsStarted 2021-07-23

Plain-language summary

This is a multicenter, multinational, retrospective chart-review study to evaluate survival in patients with Thymidine Kinase 2 deficiency (TK2d).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent by the subject or parent(s)/LAR and/or assent by the subject (when applicable), unless the associated IRB or EC provides an appropriate consent waiver that allows review of medical records for this study.
✓. Confirmed genetic mutations in the TK2 gene.
✓. Availability of medical records or information pertaining to vital status at a minimum.

What they're measuring

Number of participants who have died.

Timeframe: Start of observation period (first medical record available on site), to last medical record available on site or end of observation period on 12-Jan-2022, whichever comes first.

Trial details

NCT IDNCT05017818

SponsorZogenix MDS, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-01-21

View on ClinicalTrials.gov More Thymidine Kinase 2 Deficiency trials